Clinical Trials Browser

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03854903 2025-02-06

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Phase 1 Completed

19 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02311998 2023-07-17

Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML

Phase 1/2 Completed

22 enrolled 14 charts

MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02269267 2023-03-03

The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

Phase 2 Completed

173 enrolled 14 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02810990 2023-02-03

BEST

Phase 2 Completed

65 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03885830 2023-01-11

Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients

Completed

45 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT03023319 2022-06-14

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

Phase 1 Completed

6 enrolled

GenitourinaryGynecologicOther solid neoplasmThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Mesothelioma, Ovarian Neoplasms, Thymoma, Thymus Neoplasms

NCT02638467 2020-11-05

Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy

Phase 2 Completed

2 enrolled

Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia

NCT01331291 2016-07-25

Bosutinib in Adult Patients With Recurrent Glioblastoma

Phase 2 Completed

36 enrolled 9 charts

CNS

Glioblastoma

Clinical Trials

BosuPeg

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML

The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

BEST

Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy

Bosutinib in Adult Patients With Recurrent Glioblastoma